Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079635 | 1.00 | KCNA3 (0.53) | KCNA3SIGMAR1CYP2D6ALDH1A1LTA4H | |
| SCHEMBL6080224 | 1.00 | KCNA3 (0.53) | KCNA3SIGMAR1CYP2D6ALDH1A1LTA4H | |
| SCHEMBL9595556 | 0.89 | KCNA3 (0.47) | KCNA3SIGMAR1CYP2D6ALDH1A1KDM4E | |
| SCHEMBL6079135 | 0.88 | KCNA3 (0.64) | KCNA3SIGMAR1CYP2D6LTA4HCCR5 | |
| SCHEMBL6079873 | 0.88 | KCNA3 (0.64) | KCNA3SIGMAR1CYP2D6LTA4HCCR5 | |
| SCHEMBL6079142 | 0.88 | KCNA3 (0.64) | KCNA3SIGMAR1CYP2D6LTA4HCCR5 | |
| SCHEMBL4589190 | 0.85 | CYP2D6 (0.46) | KCNA3SIGMAR1CYP2D6ALDH1A1KDM4E | |
| SCHEMBL5857950 | 0.83 | KCNA3 (0.71) | KCNA3SIGMAR1CYP2D6CCR5 | |
| Hydrochloric Acid SCHEMBL8199416 | 0.81 | KCNA3 (0.69) | KCNA3SIGMAR1CYP2D6CCR5 | |
| Hydrochloric Acid SCHEMBL4218305 | 0.81 | KCNA3 (0.69) | KCNA3SIGMAR1CYP2D6CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-04 | — | — | US | disclosed |
| EP-1554249-A2 | 1-PYRIDIN-4-YL-UREA DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004026836-A2 | 1-PYRIDIN-4-YL-UREA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | P2RY4, P2RX4, REN | KCNA3 536/4885SIGMAR1 162/4885CYP2D6 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.